A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
102actual
Sites
21
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-25 | actual | When the study began enrolling |
| Primary completion | 2025-11-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-12 | actual | The whole study's end, after follow-up |
| First posted | 2021-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mesothelioma, Malignant
Interventions
- Biological: Nivolumab — also filed as BMS-936558, Opdivo
- Biological: Ipilimumab — also filed as BMS-734016, Yervoy
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 58 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed